
Ayuk A. Anderson†, Xavier Altafaj§, Zhenlin Zheng⁹, Zhong-Min Wang⁹, Osvaldo Delbono⁎, Michel Ronjat§, Susan Treves† and Francesco Zorzato¶**

From the †Departments of Anaesthesia and Research, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland. §INSERM U607/CEA/UJF, Lab CCFP/DRDC, Rue des Martyrs 17, 38054, Grenoble, Cedex 9 France. #Department of Physiology and Pharmacology, *Department of Internal Medicine, Gerontology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, U.S.A. ¶Department of Experimental and Diagnostic Medicine, General Pathology section, University of Ferrara, Via Borsari 46, 44100 Ferrara, Italy.

Running Title: JP-45 interacts with the skeletal muscle dihydropyridine receptor

Words: 7738

**To whom correspondence should be addressed:
Tel: +39-0532-291-356; FAX: +39-0532-247-278; E-Mail: zor@unife.it
Summary

JP-45, an integral protein of the skeletal muscle sarcoplasmic reticulum junctional face membrane, co-localizes with the sarcoplasmic reticulum calcium release channel and interacts with calsequestrin and the dihydropyridine receptor. We have identified (i) the domains of both JP-45 and of the dihydropyridine receptor involved in this interaction, and (ii) investigated the functional effect of JP-45. The cytoplasmic domain of JP-45 encompassing residues 1-80, interacts with the native dihydropyridine receptor. JP-45 interacts with two distinct and functionally relevant domains of Cav1.1 α1 subunit, namely the I-II loop and the COOH-terminal region. The interaction between JP-45 and the I-II loop occurs via the alpha-interacting domain. The β1a subunit also interacts with the cytosolic domain of JP-45 and its presence drastically reduces the interaction between JP-45 and the I-II loop. The functional effect of JP-45 on Cav1.1 activity was assessed by investigating charge movement in differentiated C2C12 myotubes after either overexpression or depletion of JP-45. Overexpression of JP-45 decreased peak charge movement and shifted $V_{Q1/2}$ to more negative potential (-10mV). JP-45 depletion decreased both the content of the α1.1 subunit and peak charge movements. Our data demonstrate that JP-45 is a protein important for functional expression of voltage dependent calcium channels.

Introduction

The skeletal muscle sarcoplasmic reticulum and the transverse tubular membranes provide a conducive environment enriched with key proteins that have been shown to play an essential role in excitation-contraction (E-C) coupling (Endo, 1985; Fleischer and Inui, 1989). E-C coupling occurs in specialized junctions called triads, which are an intracellular synapse formed by the transverse tubule membrane system and the sarcoplasmic reticulum terminal cisternae. The two main proteins involved in E-C coupling are the dihydropyridine receptor calcium channel (Cav1.1), which lies on the transverse tubules where it acts as a voltage sensor for E-C coupling, and the ryanodine receptor...
(RYR), present on the sarcoplasmic reticulum junctional face membrane, which is the Ca\(^{2+}\) release channel (Franzini-Armstrong and Jorgensen, 1994; Meissner, 1994; Ma and Pan, 2003; Sutko and Airey, 1996; Franzini-Armstrong, 1980; Lamb and Stephenson, 1990; Rios and Pizarro, 1991). The Cav1.1 is a hetero-oligomeric complex made up of at least four subunits: \(\alpha_1\), \(\beta_1\alpha\), \(\alpha_2 - \delta\) and \(\gamma\) (Leung et al., 1987; Lacerda et al., 1987; Birnbaumer et al., 1998; Catterall, 1995; Snutch and Reiner, 1992). The pore-forming \(\alpha_1\) subunit of Cav1.1 is an integral membrane protein and is indispensable for E-C coupling, whereas the cytosolic \(\beta_1\alpha\), and \(\alpha_2 - \delta\) subunits have regulatory functions; the role of the \(\gamma\) subunit has yet to be clearly defined (Catterall, 1995; Snutch and Reiner, 1992, Tsien et al., 1991). The \(\beta_1\alpha\) subunit associates tightly with the \(\alpha_1.1\) subunit by binding to a region present on the I-II loop termed alpha interacting domain (AID) (Pragnell et al., 1994). The \(\beta_1\alpha\)-subunit is important for plasma membrane expression of the \(\alpha_1.1\) subunit whereas a sequence located in the COOH-domain of the \(\alpha_1.1\) seems to be involved in triad targeting (Chien et al., 1995; Flucher et al., 2000; Flucher et al., 2002), though other domains/polypeptides may be involved in proper targeting.

In skeletal muscle, Cav1.1 responds to transverse tubule depolarisation by sensing the voltage change and it induces calcium release from the sarcoplasmic reticulum via a direct interaction with the RYR. Besides the RYR however, the junctional face membrane contains numerous other proteins, which, because of their anatomical location, are deemed to be involved in E-C coupling (Zhang et al., 1997; Costello et al., 1986; Zorzato et al., 2000). In the past few years a number of investigators have begun to define the major and minor structural components of the junctional face membrane (Ito et al., 2001; Takeshima et al. 2000). In previous studies (Zorzato et al., 2000; Anderson et al., 2003) we identified and characterized at the biochemical and molecular level JP-45, an integral membrane protein constituent of the skeletal muscle sarcoplasmic reticulum junctional face membrane. We also showed that JP-45 co-localizes with the RYR calcium release channel and interacts with Cav1.1 and the luminal calcium binding protein, calsequestrin (Anderson et al., 2003). In order to gather insight into the functional role of JP-45 we defined the domains involved in the interaction between JP-45 and Cav1.1. Our results demonstrate that the cytoplasmic domain of JP-45 interacts directly with the I-II loop, the COOH-terminal domains of \(\alpha_1.1\) subunit as well as with the \(\beta_1\alpha\) subunit. In addition we
show that the interaction between JP-45 and the I-II loop occurs via the AID domain and can be displaced by β1a. Experimental evidence has demonstrated that the β1a subunit interacts with α1.1 subunit via AID (Pragnell et al., 1994; Chen et al., 2004) and that this protein-protein interaction is involved in insertion of the voltage sensor to its proper membrane compartment (Flucher et al., 2002). In order to confirm the functional role of JP-45 in vivo, we either over-expressed or silenced endogenous JP-45 in C2C12 cells and studied the electrophysiological properties of transfected cells. Based on the results of the present report, the functional role of JP-45 is consistent with its involvement in the regulation of functional expression of the Cav1.1 into the transverse tubular membrane compartment.

**Experimental procedures Materials:**

PGex plasmids, nitrocellulose, rainbow Molecular Weight Markers, glutathione-Sepharose, and [³²P]dCTP were from Amersham Biosciences; goat anti-α1 subunit of the skeletal muscle Cav1.1 polyclonal antibodies were from Santa Cruz Biotechnology Inc.; Isopropyl-β-D-thiogalactoside (IPTG), chemiluminescence kit, restriction enzymes, fugene transfection reagent, peroxidase conjugated anti-goat antibodies, EDTA-free anti-protease cocktail were from Roche Applied Science; protein-G peroxidase, protein assay determination kit and SDS-PAG protein standards were from Bio-Rad; the TALON metal affinity resins was from BD Bioscience; tricine, anti-poly-histidine, anti-β-actin Abs and peroxidase-conjugated anti-mouse antibodies were from Sigma chemicals. Jet PEI transfection reagent was from Polyplus-Transfection SAS (Illkirch, France). Protein G plus Agarose (Santa Cruz Biotechnology, Inc., Santa Cruz, CA. The pFP-N3/DsRed2 vector was constructed by in-frame substitution of the sequence encoding EGFP in the pEGFP plasmid (Clonetech) with that of DsRed2. The sequence of the plasmid backbone used for subsequent cloning of JP-45 cDNA was confirmed by sequencing. All other chemicals were reagent of highest available grade.

**Methods:**

*Production and purification of fusion proteins:* PCR-amplified cDNA encoding overlapping sequences of mouse skeletal muscle JP-45 were cloned in-frame into the multiple cloning site of
PCR amplification conditions and primer sequences were as previously described (Anderson et al., 2003), using the following sets of primers: domain 1, encompassing residues 1-29 was amplified using the following forward and reverse primers: 5’-AGAATTCTATGACTACCAGAGGCCTGG-3’ and 5’-AGTCGACGGCTGGTCCCTCCAGAAAT-3’; domain 2, encompassing residues 1-80 was amplified using the following forward and reverse primers: 5’-AGAATTCTATGACTACCAGAGGCCTGG-3’ and 5’-AGTCGACTGTGCTCTCCTTGCCCGCTA-3’; domain 3, encompassing residues 81-125 was amplified using the following forward and reverse primers: 5’-AGAATTCTGGCAAAAGCGGGAACAA-3’ and 5’-AGTCGACATCTCCCCAGGGCAGGTC-3’; the NH2-terminus, encompassing residues 1-125 was amplified using the following forward and reverse primers: 5’-AGAATTCTTGCAAAAGCGGGAACAA-3’ and 5’-AGTCGACATCTCCCCAGGGCAGGTC-3’; the COOH-terminus, encompassing residues 149-331 was amplified using the following forward and reverse primers: 5’-AGAATTCTGGCAAAAGCGGGAACAA-3’ and 5’-AGTCGACATCTCCCCAGGGCAGGTC-3’. The EcoRI restriction enzyme sequence was added to facilitate subsequent subcloning. cDNA was amplified in a Perkin Elmer GeneAmp 2400 PCR System under the following conditions: 5 min 95°C, followed by 35 cycles of 40 sec annealing at 61°C, 45 sec extension at 72°C and 30 sec denaturation at 92°C and a final elongation step of 4 min at 72°C.

The cDNAs encoding different domains of rabbit skeletal muscle α1.1 subunit (Tanabe et al., 1987) were cloned into the pMR78 expression vector designed to express His-tagged proteins. The α1.1 subunit constructs used include the NH2-terminus (encompassing residues 1-51), the I-II loop (encompassing residues 335-432), the II-III loop (encompassing residues 654-797), the III-IV loop (encompassing residues 1059-1118), the proximal COOH-terminus (encompassing residues 1382-1585), the distal COOH-terminus (encompassing residues 1588-1878) and the full length β1a subunit. All constructs were checked by direct sequencing. Plasmids were used to transform DH5α E.coli cells and fusion protein production was induced by the addition of 100 µM of isopropyl-β-D-thiogalactoside (IPTG). Fusion proteins were purified according to the manufacturer’s
recommendations using Glutathione-Sepharose for GST-tagged fusion proteins and the TALON metal affinity resins for the His-tagged α1.1 subunit fusion proteins. The protein concentration of the purified proteins was determined using the Bio-Rad protein assay kit and bovine serum albumin as standard (Bradford, 1976). The proteins eluted from the affinity columns were analysed by SDS-PAGE or Tricine-SDS-PAGE (Schagger and von Jagow, 1987) and visualized by either Coomassie Brilliant Blue or stained with anti-poly-histidine antibodies.

Immunoprecipitation and co-immunoprecipitation experiments: Light microsomal vesicles derived from rabbit skeletal muscle were prepared as described by Saito et al. (Saito et al., 1984) Membranes were solubilized at a final concentration of 1 mg/ml, for 30 min at room temperature in a buffer composed of 1% CHAPS, 200 mM NaCl, 1 mM dithiothreitol, 50 mM Tris-HCl pH 8.5 to which the protease inhibitor cocktail was added. Co-immunoprecipitation experiments of native proteins, was performed as previously described using the monoclonal anti-JP-45 Ab (Anderson et al. 2003). In order to identify the domain(s) of JP-45 interacting with the Cav1.1, CHAPS- solublized light microsomal vesicles were incubated for 60 min with glutathione-Sepharose beads to which GST-JP-45 fusion proteins had been bound. Following low speed centrifugation, the beads were washed three times with PBS; bound proteins were eluted using glutathione elution buffer, separated on a 10% SDS-PAGE and transferred onto nitrocellulose. To identify JP-45 binding domains on the Cav1.1, the fusion protein encompassing domain 2 of JP-45 was immobilized on GST-Sepharose beads and incubated for 60 min with purified His-tagged fusion proteins covering various domains of the α1.1 subunit, including the NH2-domain, the I-II, II-III, III-IV loops, the COOH-distal and COOH-proximal domains and the β1a domain in 10 mM HEPES and 150 mM NaCl plus anti-proteases. Beads were processed as described above.

C2C12 cells were washed with PBS, treated with 1% digitonin buffer (1% digitonin, 185 mM KCl, 1.5 mM CaCl2, 10 mM HEPES pH 7.4) on ice for 1 hour and centrifuged at 10,000xg for 10 min at 4°C. The lysate (500µg total protein) was precleared by adding 0.5 µg of normal mouse IgG together with 20 µl of Protein G plus Agarose and incubated for 30 min on a rotating device at 4°C. After centrifugation at 2,500 rpm (1,000xg), the supernatant was transferred to a fresh tube on ice. Mouse
Cav1.1 α1 subunit primary antibody (IIF7) (kindly provided by Dr. Kevin P. Campbell, University of Iowa, Howard Hughes Medical Institute, Iowa City, IA) (Leung et al., 1987) was added and incubated at 4°C overnight. Then 20 µl Protein G plus Agarose was added to each tube and incubated for 2 hours. After centrifugation, the pellets were washed with PBS and resuspended in 20 µl of double strength sample buffer for 30 min at room temperature (Murray and Olendieck, 1997). The proteins were separated on a 10% SDS-PAGE gel and subsequently transferred onto PVDF membrane. Non-specific binding was blocked by incubating the membrane in 5% milk PBS for 60 minutes at room temperature. Incubation in the primary antibody (1:1000 diluted in blot buffer) was done for 2 hour at room temperature and washed three times for 5 min each with PBS. The membrane was incubated with anti-mouse IgG conjugated with horseradish peroxidase for 60 minutes, washed, and finally incubated in ECL Reagent and visualized in X-ray films. Autoradiograms were scanned and analyzed with KODAK-1D Image Analysis Software (Eastman Kodak Company, Rochester, NY).

Polyclonal antibody production and Western blot analysis: rabbit polyclonal antiserum was generated by immunizing a New Zealand White rabbit with glutathione-Sepharose purified GST-JP-45 fusion protein encompassing the cytoplasmic domain (aa 1-125) of JP-45. Serum was tested for the presence of Ab one month after immunization and subsequently the IgG fraction was purified by protein A column chromatography. Immunodetection of α1.1 subunit fusion proteins was carried out using monoclonal anti-poly-Histidine antibodies, followed by peroxidase-conjugated anti-mouse IgG; immunodetection of α1.1 subunit and JP-45 was carried out as described (Anderson et al. 2003). Immunopositive bands were visualized by chemiluminescence.

Cell Culture and transfection: The mouse C2C12 muscle cell line was obtained from American Type Culture Collection (ATCC, Rockville, MD), cultured in standard conditions and maintained in growth medium (Dulbecco's modified Eagle's medium, DMEM, supplemented with 20% foetal bovine serum, 100 units/ml penicillin and 100-μg/ml streptomycin). Cells were induced to differentiate by switching the medium to differentiation medium (DMEM supplemented with 2% horse serum, 100 units/ml penicillin and 100 μg/ml streptomycin). For overexpression experiments, C2C12 cells were transfected with the cDNA encoding JP-45, cloned in-frame into a hybrid pFP-N3/DsRed2 vector.
Briefly, two days after plating, cells were transfected by adding a solution of plasmid DNA (1µg) and 3 µl FUGENE6 previously mixed for 30 min at room temperature, to the tissue culture medium. Electrophysiological measurements were made on differentiated cells 5-6 days after cell transfection. To deplete C2C12 of JP-45, we transfected cells with a JP-45 siRNA vector pSHAG. JP-45 RNA interference oligos were designed using siRNA Wizard software available at InvivoGene webpage. We choose the GCTCAACAAAGTGCCTGGTACTGGCCTCGCTG nucleotides of JP-45 coding sequence. Complementary JP-45 RNAi oligos were synthesised according to instruction from Dr. G. Hannon, Cold Spring Harbor, annealed and ligated downstream U6 RNA polIII promoter of the pSHAG-1 vector as previously described (Treves et al., 2004). The nucleotide sequence of the JP-45 siRNA construct was verified by sequencing. For transfection experiments, C2C12 cells were plated on 12 mm diameter glass coverslips or on 100 mm diameter tissue culture dishes and once they reached 50-60% confluency they were transfected by a combination of CaPO4 and Jet PEI, using a total of 7.5 µg of plasmid DNA (coverslips) or 15 µg plasmid DNA (cell culture dishes). The day after transfection, the medium was changed and the cells were allowed to recover for 24 hours. On day three the cells were induced to differentiate by switching the medium to differentiation medium (DMEM supplemented with 2% horse serum, 100 units/ml penicillin and 100 µg/ml streptomycin) and were re-transfected as described above to increase transfection efficiency. The next day fresh differentiation medium was added and cells were allowed to differentiate for another 3 days when multinucleated myotubes were clearly visible. Total RNA was extracted from transfected cells, converted into DNA as previously described (Treves et al., 2004) and RT-PCR was carried out using JP-45 specific primers or β-actin specific primers. Western blot analysis was carried out with an Ab recognising the NH2-terminal domain of JP-45.

Charge Movement and Fluorescence Recordings: For charge movement recordings, C2C12 cells were plated on glass coverslips and mounted in a small flow-through Lucite chamber positioned on a microscope stage. Myotubes were continuously perfused with the external solution (see below) using a push-pull syringe pump (WPI, Saratoga, FL.). Cells were voltage-clamped in the whole-cell configuration of the patch-clamp (Hamill et al., 1981; Wang et al., 1999) using an Axopatch-200B
amplifier (Axon Instruments/Molecular Devices, Union City, CA). Micropipettes were pulled from borosilicate glasses (Boralex) using a Flaming Brown micropipette puller (P97, Sutter Instrument Co., Novato, CA) to obtain electrode resistance ranging from 2-4 MΩ. The composition of the internal solution (pipette) was (mM): 140 Cs-aspartate; 5 Mg-aspartate, 10 Cs₂EGTA (ethylene glycol-bis(α-aminoethyl ether)-N,N,N’N’-tetraacetic acid), 10 HEPES (N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]), pH was adjusted to 7.4 with CsOH. The high concentration of Mg²⁺ in the pipette solution helped to stabilize the preparation for longer periods of time. The external solution contained (mM): 145 TEA (tetraethylammonium)-Cl, 10 CaCl₂, 10 HEPES and 0.001 tetrodotoxin. Solution pH was adjusted to 7.4 with TEA.OH. For charge movement recording, calcium current was blocked by the addition of 0.5 Cd²⁺ plus 0.3 La³⁺ to the external solution (Hamill et al., 1981; Wang et al., 1999; Wang et al., 2000; Beam and Franzini-Armstrong, 1997).

Whole-cell currents were acquired and filtered at 5 kHz with pClamp 6.04 software (Axon). A Digidata 1200 interface (Axon) was used for A-D conversion. Membrane current during a voltage pulse, P, was initially corrected by analogue subtraction of linear components. The remaining linear components were digitally subtracted on-line using hyperpolarizing control pulses of one-quarter test pulse amplitude (~P/4 procedure) (Delbono, 1992). The four control pulses were applied before the test pulse. We recorded the charge movement corresponding to gating of the L-type Ca²⁺ channel/DHPR. To this end, we used a prepulse protocol consisting of a 2-s prepulse to -30 mV and a subsequent 5-ms repolarization to a pedestal potential of -50 mV, followed by a 12.5-ms depolarization from -50 to 50 mV with 10-mV intervals (Adams et al., 1990). The optimal duration of the prepulse defined as the value at which no further immobilization of charge movement is attained, was determined to be 2 s after testing a range of prepulses from 1 to 6 s (Wang et al, 2000). Intramembrane charge movements were calculated as the integral of the current in response to depolarizing pulses (charge on, Q_{on}) and were expressed per membrane capacitance (coulombs per farad). The complete blockade of the inward calcium current was verified by the Q_{on} – Q_{off} linear relationship. Membrane capacitance was calculated as the integral of the transient current in response to a brief hyperpolarizing pulse from -80 mV (holding potential) to –100 mV.
To correlate the level of transfection with charge movement, we recorded fluorescent intensity arising from pFP-N3/DsRed2 in either JP-45 or only pFP-N3/DsRed2 transfected cells with a Radiance 2100K1 laser scanning confocal system (Zeiss, Oberkochen, Germany). Fluorescent intensity was acquired in all the areas of the cell by using a krypton laser at 568 nm and recording the emission at 640 nm. The acquisition settings, including iris aperture (used at maximum), laser intensity, exposure, and gain were maintained unmodified from cell to cell to standardize recordings and make the comparison among cells valid. The maximum fluorescent intensity of the whole cell was analyzed in digitized images and expressed in arbitrary units (AU).

Data were analyzed using Student’s t test or analysis of variance (ANOVA). A value of $P < 0.05$ was considered significant. Data are expressed as mean ± SEM with the number of observations ($n$).

**Results and Discussion**

*Identification of interaction domains between JP-45 and Cav1.1:* In a previous report we demonstrated that JP-45 interacts with the native Cav1.1 (Anderson et al., 2003). We set out a series of experiments to identify the domains participating in this interaction. We prepared recombinant GST-fusion proteins covering different coding region of JP-45 excluding the transmembrane domain (see Fig. 1), bound them to glutathione-Sepharose beads and incubated them with solubilized light microsomal vesicles. Figure 2A shows that the cytoplasmic NH$_2$-domain of JP-45, more specifically the region contained between residues 1-80 (domain 2) interacts with native Cav1.1. No interaction was observed between any other JP-45 domains and the Cav1.1. The physiological relevance of the interaction between fusion proteins was verified by studying the effect of GST-JP-45 domain 2 on the co-immunoprecipitation of Cav1.1 with a monoclonal anti-JP-45 Ab. The interaction between native JP-45 and Cav1.1 was competed out by the presence of soluble GST-JP-45 domain 2 in the co-immunoprecipitation reaction (fig. 2B).

Extensive structure to function relationship studies on the Cav1.1 have helped define functionally relevant domain boundaries not only among the subunits making up the supramolecular complex, but also within the primary structure of each subunit (Nakai et al, 1998; Grabner et al.,
We reasoned that the physiological relevance of the interaction between Cav1.1 and JP-45 could be better understood if we first identified JP-45 binding sites within the Cav1.1 α1 subunit. JP-45 domain 2 fusion protein was immobilized on GST-Sepharose and incubated with the different His-tagged fusion proteins covering the cytoplasmic domains of the α1.1 subunit (Tanabe et al., 1987). While some of the his-tagged fusion proteins display the expected molecular mass, in some cases they had an altered molecular mass, lower than the expected value, due to the instability of the purified fusion protein (Fig. 3A, lane 3 and 7). The protein-protein interaction experiments depicted in figure 3B demonstrate that the I-II loop and the COOH-terminal domain of the of α1.1 subunit as well as the β1a subunit, interact with JP-45, whereas fusion proteins corresponding to the NH2-terminus, the II-III and III-IV loops of the α1.1 subunit do not interact with GST-JP-45 domain 2 fusion protein. In order to validate these results, we performed pull-down experiments using GST-JP-45 domain 2 as bait and solubilised light microsomal vesicles as ligand, in the presence or absence of increasing concentrations of either I-II loop or COOH-distal recombinant fusion proteins. Inhibition of Cav1.1-GST-JP-45 interaction was achieved at 3.6 and 1.25 µM of I-II loop and COOH-distal his-tag fusion proteins, respectively. To further confirm the specificity of the pull-down assay, we also investigated these interactions under native conditions, i.e. by performing co-immunoprecipitation of native JP-45 with Cav1.1 using the monoclonal anti-JP-45 Ab, in the presence or absence of competing I-II loop or COOH-distal recombinant fusion proteins. As shown in figure 3D, the presence of the competing recombinant fusion proteins substantially diminished the interaction between JP-45 and the Cav1.1 domains. Pull-down and co-immunoprecipitation assays were concordant in demonstrating that competition with the single α1.1 interacting domains (I-II loop or COOH-distal fusion proteins) was sufficient to partially inhibit the interaction. At a first glance it may be unclear how preventing the α1.1 subunit-JP-45 interaction through a single domain reduces to almost zero total binding to α1.1 subunit. A plausible explanation of the experiments described in fig. 3C and D is that the addition of an excess of either I-II loop or COOH distal loop occupy the interacting domain of the NH2-terminal domain of JP-45. Binding of the 50 amino acid long JP-45 binding sites by an excess of either 14 kDa or 30 kDa α1.1
subunit loops (I-II and COOH terminal, respectively) most likely creates a steric hindrance whereby the interaction of alternative domains within the native solubilised Cav1.1 is either displaced or strongly weakened.

Immunoprecipitation experiments revealed that JP-45 interacts with the I-II loop of the α1.1 as well as with the purified recombinant β1a subunit (fig.3B). Because the β1a subunit has been shown to interact strongly with the I-II loop of Cav1.1 α1 subunit and affect its functional expression (Flucher et al., 2000; Chien et al., 1995), in the next set of experiments we characterised in greater detail the latter protein-protein interaction.

**Effect of β1a subunit on the interaction between JP-45 and α1.1 subunit**: We investigated the role of the β1a subunit on the interaction between JP-45 and α1.1 subunit by both pull-down and co-immunoprecipitation assays (fig. 4). JP-45 domain 2 fusion protein was immobilized on GST-Sepharose and incubated with the His-tagged α1.1 subunit I-II loop fusion protein in the presence or absence of increasing concentrations of β1a fusion protein. As can be seen in Fig. 4A the presence of β1a displaces the interaction between the I-II loop and JP-45. Pull-down assays were also performed by using the solubilised light microsomal vesicles as ligand. In the latter case, the association between GST-JP-45 domain 2 and the native α1.1 subunit was remarkably lower in the presence of an excess of β1a fusion protein (Fig 4B). The displacement of the interaction between JP-45 and the α1.1 subunit by an excess of β1a, was also confirmed by performing co-immunoprecipitation experiments using anti-JP-45 antibodies to pull down the native solubilised complex (Fig. 4C). These results suggest that the presence of an excess of β1a disrupts the complex formed between Cav1.1 and JP-45.

We cannot discriminate whether JP-45 interacts either with α1.1 subunit or with β1a, or whether JP-45 interacts with both subunits by forming an oligomeric complex.

The Cav1.1 β1a subunit has been shown to bind strongly to the intracellular loop between transmembrane domain I and II of the α1.1 subunit, in a region composed of 18 amino acids displaying the motif QQ-E—L-GY—WI---E which is conserved among different isoforms. (Pragnell et al., 1994). This binding domain is also referred to as AID. It is thought that the interaction between AID and the β1a subunit is an important determinant for the stability of the Ca\(^{2+}\) channel on the
plasma membrane (Birnbaumer et al., 1998; Flucher et al., 2000; Flucher et al., 2002; Chien et al., 1995; Ahern et al., 2003; Bichet et al., 2000); in addition, the interaction between AID and β1a is regarded as the major structural determinant required for the surface expression of the Ca\(^{2+}\) channel (Chien et al. 1995; Beurg et al, 1999; Gregg et al., 1996; Jones et al., 1998). Co-expression of α1.1 and β1a subunits has been shown to increase the density and kinetics of L-type Ca\(^{2+}\) currents and experimental evidence suggest that the β1a subunit facilitates gating of the Ca\(^{2+}\) channel by increasing the coupling between charge movement and pore opening (Sheridan et al., 2003; Sheridan et al., 2004). These effects of the β1a subunit are due to its interaction with the I-II loop, a domain that also interacts with JP-45. In the next set of experiments we addressed the question of whether the β1a subunit and JP-45 share AID as binding site on the I-II loop. To address this issue we performed pull-down assays with (i) GST-I-II loop fusion protein, (ii) with a GST fusion protein encompassing AID flanked by 21 and 11 residues at the N-terminal and C-terminal ends, respectively and (iii) with a synthetic biotinylated-AID peptide. For the first two assays, GST-fusion proteins were used as bait and His-JP-45 domain 2 as ligand. The apparent molecular mass of His-JP-45 domain 2 is larger than the theoretical predicted values (approx. 31 kDa vs 14 kDa, respectively). We are confident that the apparent larger molecular mass of the His-JP-45 domain 2 fusion protein is due to the dimerisation of the fusion protein, since treatment of the His-JP-45 domain 2 with DEPC, a reagent which destroys the His tag, abolished the binding of the anti-His tag Ab (Fig.5 panel C). Western blot analysis (Fig 5A and B) demonstrates that JP-45 domain 2 is able to interact directly with the AID sequence within the I to II loop. The \textit{in vitro} interaction between the sequence containing AID and JP-45 occurs at micromolar concentrations JP-45 fusion protein. Because of such a high concentration, it is likely that under physiological conditions, the interaction between the β1a subunit and AID prevails over that of JP-45 and AID. Nevertheless, on the basis of the highly organised molecular assembly of the triad membranes, one cannot exclude the possibility that the local concentration of JP-45 in the triadic gap might be sufficient to interfere either with the high affinity interaction between the AID and β1a subunit (Pragnell et al., 1994; Sheridan et al., 2003; Strube et al., 1996). If there are no other proteins involved in the interaction with AID, our data imply that in the β1a subunit knock-out animal AID is occupied mainly by JP-45 and that such an interaction may account, at least in part, severe phenotype
of the mice (Gregg et al., 1996). Strube et al. (1996) have shown that mouse skeletal muscle cells homozygous for a null mutation in the *cchb1* gene encoding the β1a subunit of the Cav1.1 show a significant decrease in maximum charge movement and a shift in the half activation potential toward more negative potentials.

To investigate the functional effect of JP-45 we altered the stoichiometry of the JP-45/Cav1.1 supramolecular complex either by JP-45 overexpression or by JP-45 gene silencing in differentiated C2C12 myotubes, and then we examined Cav1.1 activity by measuring charge movement.

**Effect of JP-45/DsRed2 overexpression on Cav1.1 α1 subunit function:** To examine the expression of both JP45 and α1.1 subunit we carried out western blot analysis on subcellular fractions isolated from transfected cells. Fig. 6A shows a western blot of total microsome fractions from C2C12 cells transfected either with the pFP-N3/DsRed2 vector or with the JP-45/pFP-N3/DsRed2 plasmid; cells transfected with the latter plasmid show an immunoreactive band of approximately 45 kDa, which represents endogenous JP-45, and a band of approximately 70 kDa, which represents the JP-45-DsRed fusion protein. To verify whether overexpression of JP-45 affects the average content of α1.1 subunit we performed immunoprecipitation experiments. Total C2C12 lysate form control and JP45 overexpressing cells contain two distinct high molecular weight bands of 175 and 170 kDa referable to α1.1 subunit (Leung et al., 1987). The relative content of the bands did not show major change (ratio of α1.1 bands intensity in JP45 overexpressing cells vs those of cells expressing empty vector is 0.971+- 0.06, mean+-S.D.). C2C12 cells were transfected with JP-45/pFP-N3/DsRed2 and the expression of JP-45/DsRed2 fusion protein was monitored by fluorescent microscopy to perform direct charge movement measurements. Fig. 7A shows the maximal charge movement – fluorescence relationship for C2C12 cells transfected with either JP-45/pFP-N3/DsRed2 construct (A, n = 17) or pFP-N3/DsRed2 vector alone as control (B, n = 15). As the magnitude of JP-45/DsRed2 fluorescence increased, the peak charge movement significantly decreased (A), a phenomenon that was not observed in the control cells transfected only with the pFP-3/DsRed2 plasmid (B). For the analysis of the charge movement – membrane voltage relationship of cells transfected with either JP-45/pFP-
N3/DsRed2 (C) or pFP-N3/DsRed2 plasmid (D), data points were fitted to a Boltzmann equation of the form:

$$Q_{on} = \frac{Q_{max}}{1 + \exp(V_{Q1/2} - V_m)/K}, \text{ equation 1}$$

where $Q_{max}$ is the maximum charge, $V_m$ is the membrane potential, $V_{Q1/2}$ is the charge movement half – activation potential, and $K$ is the steepness of the curve. When cells were pooled for the analysis, $Q_{max}$ was significantly lower in JP-45/pFP-N3/DsRed2 transfected than in control cells, whereas $V_{Q1/2}$ was shifted to more negative potentials in the former group. The best fitting parameters for $Q_{max}$, $V_{Q1/2}$ and $K$ recorded in both groups of cells are included in Table 1. No differences in the steepness of the curve were recorded. To better characterize the voltage-dependence of the charge movement, the group of cells transfected with JP-45/pFP-N3/DsRed2 (Fig. 7A and C) were separated into two subgroups, either exhibiting the 5 maximum or minimum $Q_{max}$ values (Fig. 7E). This approach allows for the identification of a more obvious difference not only in $Q_{max}$ (~3-fold) but also in the half activation potential of the charge movement (Table 1). High levels of JP-45 expression are associated with a $V_{Q1/2}$ shift to more negative potentials of ~10mV (Fig. 7C and D). No differences in the steepness of the curve were observed between these two groups of cells (Table 1).

The observation that alteration of peak charge movement is tightly linked to the magnitude of JP-45 expression suggests that the stoichiometry of the JP-45/Cav1.1 supramolecular complex is crucial for the proper function of the Cav1.1. If this is so, we reasoned that depletion of JP-45 in differentiated myotubes would similarly affect DHPR charge movement. Thus, in the next set of experiments we investigated whether charge movement is also affected in C2C12 myotubes depleted of JP-45.

**Effect of JP-45 gene silencing on Cav1.1 function**

The mRNA encoding JP-45 was much less abundant in C2C12 myotubes transfected with the plasmid containing JP-45 siRNA than in cells transfected with the control pSHAG vector (Fig. 8A). The presence of residual mRNA for JP-45 could be due either to the presence of a small subpopulation of cells which had not been transfected with the JP-45 siRNA construct, or to the inability of the construct to fully eliminate the transcript of JP-45. The amount of β-actin transcript did not differ significantly between cells transfected with the two constructs (fig.8A lower panel). Western blot analysis was performed to confirm depletion of JP-45 in differentiated C2C12 myotubes.
As can be seen in Fig. 8B expression of JP-45 in JP-45siRNA transfected C2C12 is lower than the detection limit of the anti-JP-45 Abs which were raised against the NH$_2$-terminal interacting domain of the protein. On the other hand, we did not see changes in the expression of the house keeping gene β-actin. Having established a reduction of both transcription and expression of JP-45 we next measured Cav1.1 charge movement. C2C12 cells were co-transfected with pFP-N3/DsRed2 and either the JP-45 siRNA pSHAG vector or the pSHAG vector. Based on the expression of the reporter DsRed2 red fluorescent protein, C2C12 cells were identified and charge movement measurements were performed. Figure 9A shows that depletion of JP-45 in C2C12 myotubes is associated with a decrease in $Q_{\text{max}}$ without apparently affecting $V_{Q1/2}$ or the steepness of the curves (Table 2). Figure 9 also shows charge movement traces recorded in C2C12 cells transfected with either pSHAG (B) or JP-45 siRNA (C), respectively. The lower $Q_{\text{max}}$ in JP-45 depleted C2C12 cells may originate from a decrease of Cav1.1 content in muscle cell membrane. To verify this we quantified by Western blot analysis the relative content of $\alpha 1.1$ subunit in C2C12 membrane from JP-45 siRNA and pSHAG transfected C2C12 cells. As can be seen in Fig. 9D and E, $\alpha 1.1$ subunit shows two distinct high molecular weight bands of 175 and 170 kDa (Leung et al., 1987)). Furthermore, in C2C12 myotubes depleted of JP-45, there is a significant reduction of the immunoreactive band referable to $\alpha 1.1$ subunit (Fig. 9D and Fig. 9E). The $\alpha 1.1$ subunit expression, measured as the ratio of the immunopositive band between siRNA JP-45 and control pSHAG vector transfected C2C12 cells, was 0.63 ± 0.10 (mean ± s.e.m. n=4). The fractional decrease of $\alpha 1.1$ subunit expression is of 0.37 ± 0.09 and it matches the decrease in charge movement (fractional decrease: 0.34) shown in Table 2. These results indicate that JP-45 may be important for proper insertion of the $\alpha 1.1$ subunit into the muscle cell membrane.

A great deal of data have been obtained in the last few years concerning structural determinant(s) necessary for the proper functional insertion of Cav1.1 into the plasma membrane. Although all the aspects of the functional insertion into the membrane and of the targeting of the Cav1.1 are still not fully clear, the emerging idea is that cooperation of the alfa interacting domain in the I-II loop with the COOH terminal domain, in addition to the tertiary and quaternary structure
assembly of the Cav1.1 complex, play a crucial role in the functional expression of the Cav1.1
α subunit in the cell membrane (Flucher et al., 2002). However, the involvement of additional
protein-protein interactions between other polypeptides of the triad membrane have been implicated
for the proper functional insertion of the Cav1.1 and we suggest that JP-45 is one of these additional
polypeptides important for the proper assembly of the DHPR macromolecular complex into the
plasma membrane.

In conclusion, in the present report we have shown that JP-45 domain 2 interacts with the
AID sequence and with COOH terminal domain the Cav1.1 α subunit, two important structural
determinants for functional expression of the Cav1.1. In addition, we provided clear evidence that the
level of expression of JP-45 in C2C12 myotubes affects the functional properties and expression of
Cav1.1. By altering the expression levels of JP-45 in differentiated C2C12 myotubes either by
overexpressing its cDNA, or by JP-45 gene silencing, the stoichiometry of the JP-45/Cav1.1
supramolecular complex is dramatically altered. It is tempting to speculate that alteration of the
stoichiometry of the complex influences the functional expression of the Cav1.1 by different
mechanisms. Fig. 10 summarises a speculative model which describe the potential mode of action of
JP-45 on Cav1.1 function and underline the importance of the correct stoichiometry of the JP-
45/Cav1.1 supramolecular complex on the functional expression of Cav1.1. Overexpression of JP-45
apparently does not induce major changes in the α1.1 expression level, however it could enforce
occupation of its binding site of the I-II loop. This occupation of the JP-45 binding site within the I-II
loop may occur as consequence of a partial dissociation of the Cav1.1 β1a subunit, or via interaction
with α1.1 subunit, which does not stably bind β1a subunit (Garcia et al., 2002; Jones et al., 2002).
The I-II loop is adjacent to a repeat within the α1.1 subunit domain involved in channel gating. It is
tempting to speculate that the effect of the overexpression and binding of JP-45 to the binding site
within I-II loop is two fold:

1) interference with the β1a action on gating currents (Strube et al., 1996, Sheridan et al.,
2003);
2) perturbation of the functional role of the adjacent repeat, on channel function. Each outcome, or the combination of both, would confer an inhibited conformation of the JP-45/Cav1.1 supramolecular complex leading to a decrease in charge movement. On the other hand, as indicated by Western blot analysis, depletion of JP-45 affects the total content of the Cav1.1 in the cell membrane, and in parallel also decreases maximal charge movement. The mechanism leading to the decrease in α1.1 subunit content in cell membranes of JP-45 depleted cells may have several explanations. Firstly, our results show JP-45 interacts with the COOH terminal domain, a region which has been shown to encompass a sequence involved in membrane targeting. When such a sequence does not interact with JP-45, proper membrane targeting of Cav1.1 may be impaired. Alternatively, JP-45 is involved in stabilising the Cav1.1 complex. The functional consequence of both events is a decrease in $Q_{\text{max}}$ with no changes in voltage dependence of the charge movement.

JP-45 is expressed at very early stage of skeletal muscle development, in fact its transcript appears in 15 day old embryos (Anderson et al., 2003), i.e. in a developmental phase in which ER/SR membrane transition is not completed. In immature skeletal muscle fibres JP-45 might be localised in the ER/SR membrane network, and then in adult muscle fibres JP-45 is targeted to the sarcoplasmic reticulum junctional face membrane. JP-45 may be involved in the retention of the α subunit of Cav1.1 into the ER/SR membrane during the assembly of the Cav1.1 complex at an early stage of skeletal muscle development. The appearance of the β1a subunit will displace the interaction of between JP-45 and the I-II loop of the α1.1. Such an event along with the interaction of JP-45 with he COOH terminal targeting domain allow the functional expression of the α1.1 subunit to the transverse tubular membranes.
REFERENCES


Bichet, D., Cornet, V., Geib, S., Carlier, E., Volsen, S., Hoshi, T., Mori, Y., and DeWaard, M. (2000) The I-II loop of the Ca2+ channel alpha1 subunit contains an endoplasmic reticulum retention signal antagonized by the beta subunit Neuron 25, 177-190


Grabner, M., Dirksen, R.T., Suda, N., and Beam, K.G. (1999) The II-III loop of the skeletal muscle dihydropyridine receptor is responsible for the Bi-directional coupling with the ryanodine receptor J. Biol. Chem. 274, 21913-21919


Leung, A.T., Imagawa, T., Campbell, K. P. (1987) Structural characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca2+ channel from rabbit skeletal muscle. Evidence for two distinct high molecular weight subunits *J Biol Chem.* **262**:7943-6


Acknowledgements:
This work was supported by grants from the Schweizereische Stiftung für die Erforschung der Muskelkrankheiten, from the Association Française contre les Myopathies, from the European Union, N° HPRN-CT-2002-00331 and from F.I.R.BRAU01ERMX, PRIN05. This work was also supported from the Department of Anaesthesia, University Hospital Basel and by grants AG18755, AG13934 and AG15820 from the National Institute of Health/National Institute on Aging, USA.

Abbreviations:
AID, alpha interacting domain; Cav1.1, dihydropyridine receptor; E-C coupling, excitation-contraction coupling; RYR, ryanodine receptor.
**TABLE 1**

Best-fitting parameters describing the voltage-dependence of charge movement in JP-45 overexpressing C2C12 myotubes

<table>
<thead>
<tr>
<th></th>
<th>Best-fitting parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$Q_{\text{max}}$ (nC µF$^{-1}$)</td>
</tr>
<tr>
<td><strong>JP-45 transfected</strong>&lt;br&gt;N = 17</td>
<td>6.4 ± 0.3</td>
</tr>
<tr>
<td><strong>Only vector</strong>&lt;br&gt;transfected cells&lt;br&gt;N = 15</td>
<td>8.9 ± 0.3 (*)</td>
</tr>
<tr>
<td><strong>JP-45</strong>&lt;br&gt;Max Q values&lt;br&gt;(n = 5)</td>
<td>10.1 ± 1.0</td>
</tr>
<tr>
<td><strong>JP-45</strong>&lt;br&gt;Min Q values&lt;br&gt;(n = 5)</td>
<td>3.2 ± 0.04 (**)</td>
</tr>
</tbody>
</table>

Statistically significant difference between cells transfected with either JP-45 or only vector (*) and between JP-45 maximum (Max) and minimum (Min) charge movement (Q) values (**) ($P < 0.05$). N, number of cells. ns, not significant. Values are mean ± SEM.

**TABLE 2**

Best-fitting parameters describing the voltage-dependence of charge movement in JP-45 siRNA and pSHAG transfected C2C12 myotubes

<table>
<thead>
<tr>
<th></th>
<th>Best-fitting parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$Q_{\text{max}}$ (nC µF$^{-1}$)</td>
</tr>
<tr>
<td><strong>JP-45 siRNA</strong>&lt;br&gt;N = 18</td>
<td>5.8 ± 0.37</td>
</tr>
<tr>
<td><strong>pSHAG vector</strong>&lt;br&gt;N = 17</td>
<td>8.7 ± 0.41 (*)</td>
</tr>
</tbody>
</table>

Values are means ± SEM. N, number of cells. Values are mean ± SEM. (*) $P < 0.05$
Figure Legends

**Figure 1: Domains of JP-45 used to identify the Cav1.1 binding sites.**

* A. Schematic representation.
* B. 10% SDS PAG and Coomassie Brilliant Blue staining of the GST-JP-45 fusion proteins purified by glutathione-Sepharose. The numbers above each lane indicate the amino acid residues which were fused in frame in the pGex plasmid to yield the GST-JP-45 fusion protein.

**Figure 2: Identification of the JP-45 domain interacting with Cav1.1.**

* A. GST-JP-45 fusion proteins encompassing different domains of JP-45 were bound to glutathione-Sepharose beads and incubated with solubilized rabbit skeletal muscle microsomal vesicles as described in the Methods section. The proteins present in the void (V), last wash (LW) and those bound (B) to the beads were separated on a 10% SDS PAG, transferred onto nitrocellulose and the presence of the bound Cav1.1 was revealed by Western blotting using commercial anti-α1.1 antibodies.
* B. Co-immunoprecipitation experiment using monoclonal anti-JP-45 Ab to pull down the Cav1.1. Experiments were performed as described in the Methods section: where indicated recombinant GST-JP-45 domain 2 was used to compete out the interaction between endogenous proteins present in the microsomes forming a supramolecular complex.

**Figure 3: Identification of Cav1.1 domains interacting with JP-45.**

* A. Immunoblot of purified His-tagged fusion proteins encompassing the different α1.1 domains (10% Tricine SDS PAG) and β1a (10% SDS PAG). Immunostaining was carried out using commercial anti-poly-His antibodies followed by peroxidase conjugated anti-mouse IgG; bands were visualized by chemiluminescence.
* B. Pull-down of His-tagged fusion proteins with domain 2 of JP-45 (aa residue 1-80). GST-JP-45 domain 2 fusion protein was bound to glutathione-Sepharose beads and incubated with the His-tagged recombinant α1.1 proteins. Proteins present in the void (V) or bound to the beads (B) were separated on a 10% tricine SDS PAG or 10% SDS PAG (for the β1a subunit), blotted onto nitrocellulose and visualized by Western blot using anti-poly-His Ab as described above.
* C. GST-JP-
45 domain 2 fusion protein was bound to glutathione-Sepharose beads and incubated with solubilized light sarcoplasmic reticulum vesicles isolated from rabbit skeletal muscle in the presence of the indicated concentration of competing His-tagged I-II loop or COOH-distal fusion proteins. D. Monoclonal anti-JP-45 antibodies were used to co-immunoprecipitate the complex from solubilized light microsomal vesicles isolated from rabbit skeletal muscle in the presence of the indicated concentration of competing His-tagged I-II loop or COOH-distal fusion proteins. Proteins bound to the beads were separated in a 10% SDS PAG, transferred onto nitrocellulose and probed with antiα1.1 antibodies.

**Figure 4: Effect of the β1a subunit on the interaction between JP-45 and Cav1.1.** A. Interaction between GST-JP-45 and His I-II loop in the presence of competing purified β1a subunit. For the fusion-protein protein interaction, 0.57 µM of GST-JP-45 domain 2 and 1.4 µM I-II loop fusion protein were incubated in the presence of the indicated concentration of His-tagged β1a subunit. His tagged I-II loop fusion proteins bound to the GST-JP-45 domain 2 coated glutathione-Sepharose beads were separated on a 10% tricine SDS PAG and probed with anti-poly-His Ab as described in the legend to figure 3. B. Solubilized rabbit skeletal muscle light sarcoplasmic reticulum vesicles were incubated with GST-JP-45 domain 2-coated glutathione-Sepharose beads in the absence or presence of purified β1a subunit. Proteins present in the void (V) and bound to the beads (B), were separated on a 10% SDS PAG, blotted onto nitrocellulose and probed with antiα1.1 subunit Ab. C. Solubilized rabbit skeletal muscle light sarcoplasmic reticulum vesicles were incubated with anti-JP-45 Ab followed by incubation with Sepharose-protein G beads in the absence or presence of competing purified β1a subunit. Proteins present in the void (V) and bound (B) to the beads, were separated on a 10% SDS PAG, blotted onto nitrocellulose and probed with anti-α1.1 subunit Ab.

**Figure 5: JP-45 interacts with the AID domain on the I-II loop of Cav1.1.** A. A GST-I-II loop fusion protein or the GST-AID containing domain encompassed within α1.1 residues 336-384 were incubated with His-tagged JP-45 domain 2. Pull down was performed as described in figure 3;
proteins in the void (V), last wash (LW) or bound (B) to the glutathione resin were separated on a 12.5% SDS PAG, transferred onto nitrocellulose and probed with affinity-purified anti-JP-45 Ab. B. A synthetic biotinylated peptide corresponding to the AID sequence or an unrelated biotinylated peptide were used to coat Neutroavidine beads, which were subsequently incubated with His-JP-45 domain 2. Proteins present in the void, last wash or bound to the beads were separated on a 12.5% SDS PAG, transferred onto nitrocellulose and the immunopositive band was visualized using anti-His-tag commercial Abs. C. A his-tagged fusion protein encompassing domain 2 JP-45 was prepared as described in the Methods section. Though the fusion protein migrated slower in SDS-PAG, its identity was verified by direct sequencing (not shown), by immunoblotting using anti-His Ab. Note that treatment of the fusion protein with DTT+DEPC eliminated its immunoreactivity.

Figure 6: Overexpression of JP-45 in C2C12 cells does not affect the expression level of α1.1 subunit. C2C12 cells were transfected either with the pFP-N3/DsRed2/JP-45 vector or with pFP-N3/DsRed2 alone as control. Panel A- Microsomes were prepared from transfected differentiated C2C12; 5 µg protein were separated on a 10% SDS PAG, blotted onto nitrocellulose and probed with anti-JP-45 polyclonal Ab, followed by protein G peroxidase. The immunoreactive band was visualized by chemiluminescence. Note that control cells show the endogenous JP-45 immunoreactive band alone, while cells transfected with the pFP-N3/DsRed2/JP-45 vector show an additional band of approximately 70 kDa, representing the DsRed/JP-45 fusion protein. Panel B- immunoprecipitation and Western blot analysis of α1.1 subunit expression in C2C12 cells transfected with pFP-N3/DsRed2 or pFP-N3/DsRed2/JP-45. Results are representative of transfection experiments performed three different times.

Figure 7: Effect of JP-45 overexpression on Cav1.1 charge movement. Maximum charge movement – fluorescence relationship for C2C12 cells transfected with either pFP-N3/DsRed2 JP-45 (A) or pFP-N3/DsRed2 alone as control (B). The lines in A and B represent the linear regression including all data points. Charge movement – Vm relationship for pFP-N3/DsRed2 JP-45 (C) or pFP-
N3/DsRed2 plasmid \( D \) transfected cells fitted to a Boltzmann equation 1 (see text). The best fitting parameters are included in Table 1. Charge movement-Vm relationship for the five top and bottom \( Q_{\text{max}} \) values \( E \) from JP-45 transfected cells \( C \).

**Figure 8: JP-45 gene silencing in differentiated C2C12 myotubes.** A. Total RNA was extracted from transfected and differentiated C2C12 cells, converted into cDNA and the cDNA encoding JP-45 and \( \beta \)-actin was amplified by PCR. Amplified DNA obtained from 50 or 100 ng RNA was separated on a 7.5% acrylamide gel (JP-45, Top Panel) or a 1% agarose gel (\( \beta \)-actin, Bottom Panel). B. Microsomal proteins from transfected and differentiated C2C12 cells were prepared, separated on a 10% SDS PAG, blotted onto nitrocellulose and probed with anti-JP-45 Abs (central panel) or commercial anti-\( \beta \)-actin Abs, followed by peroxidase-labelled secondary Abs. Immunoreactive bands were visualized by chemiluminescence. Panel on the right shows blotted proteins stained with Ponceau Red. Results are representative of experiments carried out on three different transfection experiments.

**Figure 9: JP-45 gene silencing modifies Cav1.1 charge movement.** Charge movement – membrane voltage (Vm) relationship recorded in C2C12 cells transfected with JP-45 siRNA (triangles) \( n = 18 \). Control cells were transfected with pSHAG vector (circles) \( n = 17 \). A illustrate data points, expressed as means ± S.E.M., were fitted to a Boltzmann equation (equation 1). Best fitting parameters are shown in Table 2. B and C illustrate charge movement records in the -30 to +30mV range. Numbers on the left indicate the membrane potential. Dotted lines represent the baseline. D and E show immunoprecipitation and western blot analysis of Cav1.1 \( \alpha_1 \) subunit expression in C2C12 cells transfected with siRNA JP-45 and control pSHAG vector. D and E represent two from a total of 4 assays. The Cav1.1 \( \alpha_1 \) subunit expression in D and E decreased by 69 and 28%, respectively. The location of the molecular weight standards and their \( M_r \) values are depicted on the right.
Figure 10: Model depicting potential functional role of JP-45
Figure 1

A

\[ \text{cytosol} \quad TM \text{ domain} \quad \text{lumen} \]

\[
\begin{array}{c}
\text{NH}_2 \\
1-29 \\
1-80 \\
81-125 \\
1-125 \\
149-331 \\
\text{COOH}
\end{array}
\]

B

<table>
<thead>
<tr>
<th>GST+JP-45 (aa)</th>
<th>GST</th>
<th>1-29</th>
<th>1-80</th>
<th>81-125</th>
<th>149-331</th>
</tr>
</thead>
<tbody>
<tr>
<td>200 &gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>97 &gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66 &gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45 &gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31 &gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 2

A  GST-JP-45 fusion protein interaction with the DHPR

V  LW  B  V  LW  B  V  LW  B  V  LW  B

200 > 97 > 66 > 45 > 31 >

domain 1  domain 2  domain 3  NH2-term  COOH-term
aa 1-29  aa 1-80  aa 81-125  aa 1-125  aa 149-331

B  Excess GST-JP-45

kDa  (µM)  0  0.14  0.28

200 > 97 > 60 > 45 > 31 >
Figure 3

A

NH2-domain
I-II loop
II-III loop
III-IV loop
C-prox domain
C-distal domain

B

HIS-TAGGED FUSION PROTEIN INTERACTION

NH2 domain
I-II loop
II-III loop
III-IV loop
C-prox domain
C-distal domain

B1a subunit

V B

C

GST-JP-45 DOMAIN 2-LIGHT SR VESICLE INTERACTION

added I-II loop fusion protein
added C-distal fusion protein

kDa
200>
97>
66>
31>
0
0.90
3.6

D

CO-IMMUNOPRECIPITATION

added I-II loop fusion protein
added C-distal fusion protein

kDa
200>
97>
66>
31>
0
0.45
0.90
0
0.15
0.31 (pM)
Figure 4

A

FUSION PROTEIN INTERACTION (GST-JP-45/His I-II LOOP±β1a)

<table>
<thead>
<tr>
<th>μM</th>
<th>0</th>
<th>0.1</th>
<th>0.25</th>
<th>0.36</th>
<th>0.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>kDa</td>
<td>&lt;β1a&gt;</td>
<td>&lt;β1a&gt;</td>
<td>14&gt;</td>
<td>6&gt;</td>
<td></td>
</tr>
</tbody>
</table>

B

GST-JP45-LIGHT SR INTERACTION

<table>
<thead>
<tr>
<th>GST-JP-45/DHPR</th>
<th>0</th>
<th>+ 0.36 μM β1a</th>
</tr>
</thead>
<tbody>
<tr>
<td>kDa</td>
<td>V</td>
<td>B</td>
</tr>
<tr>
<td>200&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>66&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

CO-IMMUNOPRECIPITATION

<table>
<thead>
<tr>
<th>JP-45/DHPR</th>
<th>0</th>
<th>+ 0.36 μM β1a</th>
</tr>
</thead>
<tbody>
<tr>
<td>kDa</td>
<td>V</td>
<td>B</td>
</tr>
<tr>
<td>200&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>66&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 5

A  affinity purified anti-JP-45 Ab

B  anti-his-tag Ab

C  anti-his tag Ab

<table>
<thead>
<tr>
<th>BAIT</th>
<th>LIGAND</th>
<th>DEPC/DTT kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>GST I-II domain</td>
<td>GST - AID (336-384)</td>
<td>- +</td>
</tr>
<tr>
<td>biotinylated-AID</td>
<td>biotinylated-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>unrelated peptide</td>
<td></td>
</tr>
</tbody>
</table>

Note: The figure shows a protein blot analysis with different conditions and controls.
Figure 6
Figure 7

A. JP-45 transfected cells

B. pFP-N3/DsRed2 transfected cells

C. Charge movement (nC/µF) vs. Vm (mV)

D. Charge movement (nC/µF) vs. Vm (mV)

E. Charge movement (nC/µF) vs. Vm (mV)
Figure 9

A

![Graph showing charge movement vs. Vm (mV) with data points for JP-45 siRNA and pSHAG vector]

B

![Graphs showing current responses at different voltages (30 mV, 10 mV, -10 mV, -30 mV) with a scale of 500 pA and 10 ms]

C

D

![Image showing protein bands for pSHAG siRNA JP-45 with molecular weights of 175 kDa and 170 kDa]

E

![Image showing protein bands for pSHAG siRNA JP-45 with molecular weights of 175 kDa and 170 kDa]
Figure 10

Wild type

Overexpression JP-45

JP-45 knock-down

T Tubule membrane
Targeting sequence
Junctional SR membrane

Functional insertion of alpha 1.1 into sarcotubular membrane

Inhibited conformation of the JP45/Cav1.1 supramolecular complex

Low density of alpha 1.1 into skeletal muscle membrane